Studying the possible association between AI and cognitive dysfunction has accelerated over the past 7 years. A pilot study using neuropsychological testing from the Arimidex, Tamoxifen, Alone or ...

In a long awaited approveall, The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in ...

As mortality in breast cancer patients has improved, morbidity of treatment has become increasingly important. Cognitive dysfunction has been considered as a morbid condition that may possibly ...

Burnett-Bowie et al. investigated the efficacy and safety of the synthetic aromatase inhibitor anastrozole to treat hypogonadism in aging men. The study enrolled 88 men (60 years or older ...

Artificial intelligence (AI)-aided analysis of pathology slides showed potential as a predictive biomarker for non-small cell lung cancer (NSCLC) response to immune checkpoint inhibitors (ICIs), a ...

CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, announced ...

CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical ... clinical trial evaluating pocenbrodib, a CBP/p300 inhibitor, alone and in combination with abiraterone ...

(MENAFN- GlobeNewsWire - Nasdaq) CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (), a clinical-stage biotechnology company focused on re-engineering drug development through artificial ...

A novel, allosteric and highly potent USP1 inhibitor, LAE120 exhibits robust ... the progress of drug discovery leveraging cutting-edge AI models Another potential anti-tumor drug candidate ...